1. Home
  2. SAGE vs NEXN Comparison

SAGE vs NEXN Comparison

Compare SAGE & NEXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SAGE
  • NEXN
  • Stock Information
  • Founded
  • SAGE 2010
  • NEXN 2007
  • Country
  • SAGE United States
  • NEXN Israel
  • Employees
  • SAGE N/A
  • NEXN N/A
  • Industry
  • SAGE Biotechnology: Pharmaceutical Preparations
  • NEXN Computer Software: Programming Data Processing
  • Sector
  • SAGE Health Care
  • NEXN Technology
  • Exchange
  • SAGE Nasdaq
  • NEXN Nasdaq
  • Market Cap
  • SAGE 444.1M
  • NEXN 527.2M
  • IPO Year
  • SAGE 2014
  • NEXN 2021
  • Fundamental
  • Price
  • SAGE $7.50
  • NEXN $8.78
  • Analyst Decision
  • SAGE Hold
  • NEXN Buy
  • Analyst Count
  • SAGE 20
  • NEXN 7
  • Target Price
  • SAGE $10.56
  • NEXN $10.43
  • AVG Volume (30 Days)
  • SAGE 1.6M
  • NEXN 444.4K
  • Earning Date
  • SAGE 04-24-2025
  • NEXN 03-05-2025
  • Dividend Yield
  • SAGE N/A
  • NEXN N/A
  • EPS Growth
  • SAGE N/A
  • NEXN N/A
  • EPS
  • SAGE N/A
  • NEXN 0.51
  • Revenue
  • SAGE $41,243,000.00
  • NEXN $365,477,000.00
  • Revenue This Year
  • SAGE $105.47
  • NEXN $5.43
  • Revenue Next Year
  • SAGE $67.53
  • NEXN N/A
  • P/E Ratio
  • SAGE N/A
  • NEXN $17.22
  • Revenue Growth
  • SAGE N/A
  • NEXN 10.09
  • 52 Week Low
  • SAGE $4.62
  • NEXN $4.71
  • 52 Week High
  • SAGE $22.18
  • NEXN $11.00
  • Technical
  • Relative Strength Index (RSI)
  • SAGE 60.15
  • NEXN 47.17
  • Support Level
  • SAGE $7.07
  • NEXN $6.93
  • Resistance Level
  • SAGE $7.64
  • NEXN $9.90
  • Average True Range (ATR)
  • SAGE 0.27
  • NEXN 0.69
  • MACD
  • SAGE 0.00
  • NEXN 0.01
  • Stochastic Oscillator
  • SAGE 78.74
  • NEXN 45.45

About SAGE Sage Therapeutics Inc.

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.

About NEXN Nexxen International Ltd. American Depository Shares

Nexxen International Ltd empowers advertisers, agencies, publishers, and broadcasters to utilize video and connected TV. It is a demand-side platform (DSP), supply-side platform (SSP), ad server, and data management platform (DMP) and also delivers a flexible and unified technology stack with advanced and exclusive data at its core.

Share on Social Networks: